Leadership changes, September 2026
Executive appointments and departures from SEC 8-K filings, updated within hours of each filing.
Updated Nov 6, 2026
Changes
1,052
Appointments
619
Departures
64
Browse by role
September 2026
Get new CFO appointments the day the filing lands.
Filters
1,052 changes
| Filing date | Company | Person | Role | Change | Effective date | Source |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | FULLER H B CO | Ruth S. Kimmelshue | member of the Board of Directorsmember of the Board of Directors | Departed | Sep 23, 2026 | SEC 8-K |
| Sep 28, 2026 | FULLER H B CO | R. Jeffrey Bailly | Class I directorClass I director | Appointed | Sep 23, 2026 | SEC 8-K |
| Sep 28, 2026 | Gain Therapeutics, Inc. | Gianluca Fuggetta | Senior Vice President of Finance, principal financial officer, and principal accounting officerCFO | Departed | Sep 30, 2026 | SEC 8-K |
| Sep 28, 2026 | Gain Therapeutics, Inc. | Gene Mack | interim Chief Financial OfficerCFO | Appointed | Oct 1, 2026 | SEC 8-K |
| Sep 28, 2026 | GRAPHIC PACKAGING HOLDING CO | Aditya J. Gandhi | Vice President and Chief Accounting OfficerVice President and Chief Accounting Officer | Appointed | Sep 28, 2026 | SEC 8-K |
| Sep 28, 2026 | HAIN CELESTIAL GROUP INC | Michael J. Ragusa | Senior Vice President, Chief Accounting Officer and principal accounting officerSenior Vice President, Chief Accounting Officer and principal accounting officer | Departed | Nov 1, 2026 | SEC 8-K |
| Sep 28, 2026 | Humacyte, Inc. | Scott Coward | Class I directorClass I director | Appointed | Sep 22, 2026 | SEC 8-K |
| Sep 28, 2026 | Humacyte, Inc. | Paul Kuznik | Class II directorClass II director | Appointed | Sep 22, 2026 | SEC 8-K |
| Sep 28, 2026 | Jasper Therapeutics, Inc. | Herb Cross | Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate SecretaryCFO | Departed | Oct 9, 2026 | SEC 8-K |
| Sep 28, 2026 | Jasper Therapeutics, Inc. | Jeet Mahal | interim Principal Financial Officerinterim Principal Financial Officer | Appointed | Oct 9, 2026 | SEC 8-K |
| Sep 28, 2026 | Jasper Therapeutics, Inc. | Rick Ruiz | interim Principal Accounting Officerinterim Principal Accounting Officer | Appointed | Oct 9, 2026 | SEC 8-K |
| Sep 28, 2026 | Jasper Therapeutics, Inc. | Matthew Ros | interim Corporate Secretaryinterim Corporate Secretary | Appointed | Oct 9, 2026 | SEC 8-K |
| Sep 28, 2026 | Matternet, Inc. | Jason Secore | Chief Financial OfficerCFO | Departed | Sep 29, 2026 | SEC 8-K |
| Sep 28, 2026 | Matternet, Inc. | Andreas Raptopoulos | Chief Financial OfficerCFO | Appointed | Sep 29, 2026 | SEC 8-K |
| Sep 28, 2026 | MongoDB, Inc. | Chirantan (“CJ”) Desai | President and Chief Executive OfficerCEO | Departed | Sep 28, 2026 | SEC 8-K |
| Sep 28, 2026 | MongoDB, Inc. | Dev Ittycheria | Interim President and Chief Executive OfficerCEO | Appointed | Sep 28, 2026 | SEC 8-K |
| Sep 28, 2026 | NEUROCRINE BIOSCIENCES INC | Eiry W. Roberts, M.D. | Chief Medical OfficerCMO | Appointed | Sep 28, 2026 | SEC 8-K |
| Sep 28, 2026 | NEUROCRINE BIOSCIENCES INC | Sanjay Keswani, M.D. | Chief Medical OfficerCMO | Departed | Sep 25, 2026 | SEC 8-K |
| Sep 28, 2026 | QUANTUM CORP /DE/ | James C. Clancy | Chief Operating OfficerCOO | Appointed | Sep 28, 2026 | SEC 8-K |
| Sep 28, 2026 | QUANTUM CORP /DE/ | James C. Clancy | member of the Company’s Board of Directorsmember of the Company’s Board of Directors | Departed | Sep 28, 2026 | SEC 8-K |
- FULLER H B CODeparted
Ruth S. Kimmelshue member of the Board of Directors
Filed Sep 28, 2026Effective Sep 23, 2026SEC 8-K
- FULLER H B COAppointed
R. Jeffrey Bailly Class I director
Filed Sep 28, 2026Effective Sep 23, 2026SEC 8-K
- Gain Therapeutics, Inc.Departed
Gianluca Fuggetta CFO
Filed Sep 28, 2026Effective Sep 30, 2026SEC 8-K
- Gain Therapeutics, Inc.Appointed
Gene Mack CFO
Filed Sep 28, 2026Effective Oct 1, 2026SEC 8-K
- GRAPHIC PACKAGING HOLDING COAppointed
Aditya J. Gandhi Vice President and Chief Accounting Officer
Filed Sep 28, 2026Effective Sep 28, 2026SEC 8-K
- HAIN CELESTIAL GROUP INCDeparted
Michael J. Ragusa Senior Vice President, Chief Accounting Officer and principal accounting officer
Filed Sep 28, 2026Effective Nov 1, 2026SEC 8-K
- Humacyte, Inc.Appointed
Scott Coward Class I director
Filed Sep 28, 2026Effective Sep 22, 2026SEC 8-K
- Humacyte, Inc.Appointed
Paul Kuznik Class II director
Filed Sep 28, 2026Effective Sep 22, 2026SEC 8-K
- Jasper Therapeutics, Inc.Departed
Herb Cross CFO
Filed Sep 28, 2026Effective Oct 9, 2026SEC 8-K
- Jasper Therapeutics, Inc.Appointed
Jeet Mahal interim Principal Financial Officer
Filed Sep 28, 2026Effective Oct 9, 2026SEC 8-K
- Jasper Therapeutics, Inc.Appointed
Rick Ruiz interim Principal Accounting Officer
Filed Sep 28, 2026Effective Oct 9, 2026SEC 8-K
- Jasper Therapeutics, Inc.Appointed
Matthew Ros interim Corporate Secretary
Filed Sep 28, 2026Effective Oct 9, 2026SEC 8-K
- Matternet, Inc.Departed
Jason Secore CFO
Filed Sep 28, 2026Effective Sep 29, 2026SEC 8-K
- Matternet, Inc.Appointed
Andreas Raptopoulos CFO
Filed Sep 28, 2026Effective Sep 29, 2026SEC 8-K
- MongoDB, Inc.Departed
Chirantan (“CJ”) Desai CEO
Filed Sep 28, 2026Effective Sep 28, 2026SEC 8-K
- MongoDB, Inc.Appointed
Dev Ittycheria CEO
Filed Sep 28, 2026Effective Sep 28, 2026SEC 8-K
- NEUROCRINE BIOSCIENCES INCAppointed
Eiry W. Roberts, M.D. CMO
Filed Sep 28, 2026Effective Sep 28, 2026SEC 8-K
- NEUROCRINE BIOSCIENCES INCDeparted
Sanjay Keswani, M.D. CMO
Filed Sep 28, 2026Effective Sep 25, 2026SEC 8-K
- QUANTUM CORP /DE/Appointed
James C. Clancy COO
Filed Sep 28, 2026Effective Sep 28, 2026SEC 8-K
- QUANTUM CORP /DE/Departed
James C. Clancy member of the Company’s Board of Directors
Filed Sep 28, 2026Effective Sep 28, 2026SEC 8-K